CJC-1295 With DAC vs Without DAC: The Half-Life Split That Defines Two Compounds
'CJC-1295' is not one molecule. The DAC and no-DAC versions are kinetically distinct research compounds separated by albumin binding. A research-framed look at the mechanism of the split, what it means for pulsatility, and why it's a verification step.
The single most important fact about CJC-1295 is one the name actively hides: "CJC-1295" is not one compound. It refers to two kinetically distinct research peptides separated by a small molecular addition called DAC. Those two versions share a backbone and a receptor but behave so differently in circulation that treating them as interchangeable is a category error — and a common one. This article focuses narrowly on that with-DAC-versus-without-DAC split: the mechanism behind it, what it does to the half-life, why it matters for the pulsatile growth-hormone axis, and why confirming DAC status is a verification step rather than a footnote. Everything is framed for laboratory research use only.
Framing up front: CJC-1295 is not FDA-approved in either form. All references below describe how the compounds are characterized in research, not human outcomes, and nothing here is dosing or usage guidance.
The shared starting point
Both versions begin from the same place. CJC-1295 is a modified GHRH(1-29) analog — a stabilized version of the first 29 amino acids of growth-hormone-releasing hormone, engineered through amino-acid substitutions to resist the enzymes that would otherwise degrade it quickly. Both versions act on the GHRH receptor on pituitary somatotrophs, the same door the endogenous hormone uses to stimulate growth-hormone release. We map this receptor against the ghrelin-receptor class in GHRP vs GHRH explained, and compare CJC-1295 to the shorter Sermorelin fragment in CJC-1295 vs Sermorelin.
So far, with and without DAC are identical. The split happens entirely at the level of how long the molecule lingers.
What DAC actually is
DAC — Drug Affinity Complex — is a maleimide group added to the peptide. Maleimide is a reactive chemistry that forms a covalent bond with a free thiol, and in circulation the most abundant available thiol target is serum albumin, the body's most plentiful blood protein. So a CJC-1295 molecule carrying DAC effectively latches onto albumin and rides along with it.
The consequence is dramatic. Free peptides are cleared from circulation quickly; albumin has a long residence time. By binding albumin, the DAC version inherits a much longer effective half-life — extending the molecule's window of action from minutes into a far longer span. The no-DAC version has no such anchor and is cleared on a peptide's ordinary, short timescale.
DAC is a maleimide group that binds CJC-1295 covalently to serum albumin. With it, the compound is long-acting; without it (mod-GRF 1-29), it behaves like a stabilized short-acting GHRH analog. Same backbone, same receptor — completely different kinetics. Confirm which one the COA describes before assuming anything about duration.
Why the half-life split changes the research question
The growth-hormone axis is pulsatile. Endogenous GH is not secreted as a steady stream; it comes in discrete bursts, and the body's regulatory feedback is tuned to that rhythm. This makes duration of action not a minor convenience but a core experimental variable.
- CJC-1295 without DAC (mod-GRF 1-29) produces a relatively brief, sharper signal that more closely tracks the natural pulse shape. It is studied when the research question is about a stimulus that approximates physiological pulsatility.
- CJC-1295 with DAC produces sustained, broad receptor engagement — a continuous push rather than a discrete pulse — which departs from the natural pattern. It is studied when the question concerns prolonged GHRH-receptor stimulation.
Neither is "better." They answer different questions, and the right choice follows the question. Our explainer on peptide half-life and timing covers why pulsatility puts timing at the center of this entire class, and the growth-hormone goals page situates the secretagogue compounds in their research context.
Side by side
| Property | CJC-1295 without DAC | CJC-1295 with DAC |
|---|---|---|
| Common label | mod-GRF 1-29 | CJC-1295 DAC |
| Backbone | Modified GRF 1-29 | Modified GRF 1-29 + DAC |
| Albumin binding | No | Yes (covalent, via maleimide) |
| Relative half-life | Short, stabilized | Markedly extended |
| Signal shape (studied) | Brief, closer to pulse | Sustained, broad |
| Receptor | GHRH receptor | GHRH receptor |
The table makes the point: every row is identical except the ones DAC controls. The compounds diverge on exactly one axis — duration — and that axis governs everything downstream.
How CJC-1295 actually appears in the market
In practice, CJC-1295 most often shows up not standalone but as half of the CJC-1295 / Ipamorelin pairing. The rationale is mechanistic: Ipamorelin acts on the separate ghrelin/GHS receptor, so pairing a GHRH analog with a GHRP engages two independent pathways to the same endpoint. We cover that pairing's research logic in the CJC-1295 / Ipamorelin buyer's guide, and its catalog dossier lives at CJC-1295 / Ipamorelin within the peptide reference library. When CJC-1295 appears in a blend, the DAC question still applies — a blend can pair Ipamorelin with either the DAC or no-DAC version, so the blend's documentation has to specify which.
Why DAC status is a verification step
Because "CJC-1295" spans two kinetically different compounds, identity confirmation carries more weight here than for a single-form peptide. The practical bar:
- The COA must state DAC status, and the identity data must back it up. Mislabeling the DAC variant — or leaving it ambiguous — is a documented failure mode in this market.
- Mass-spec identity matters. The DAC group changes the molecule's mass, so the observed mass on a batch-specific Certificate of Analysis is where DAC status gets confirmed, not just asserted.
- Hold the usual standard otherwise. Reversed-phase HPLC purity, batch-specific COA, named third-party lab. Our guide to reading a peptide COA covers reading the identity section, and the buying guides cover vendor verification.
Bottom line
CJC-1295's defining complication is internal: the name covers two compounds, not one, and DAC is the entire difference between them. The maleimide group that defines the DAC version binds it to albumin and stretches its half-life from minutes to a long window, turning a short-acting GHRH analog into a sustained one. Because the growth-hormone axis is pulsatile, that duration difference changes the research question the compound can answer — which is why "with or without DAC" is not a detail but the first thing to pin down. And because the two are genuinely different molecules, confirming DAC status from the COA's identity data is a verification step, not a footnote. Source on documentation, and never assume duration from the name alone.
For research use only. Not FDA-approved, not for human consumption. Nothing here is dosing or usage guidance.
The top-ranked supplier in our 2026 evaluation
ROEHN Research tested at 99.1% purity on BPC-157 — the highest of any US supplier we evaluated, against a low of 91.3%. Readers save 15% on a first order with code FREE15.
- Cold-chain shipped
- Batch CoA in every box
- 30-day re-test policy
- 98%+ verified purity
Disclosure: Peptide Research Review maintains affiliate relationships with some of the suppliers we reference. Affiliate status has no influence on our research framing. Read our editorial policy and methodology.
Get the full 38-sample purity report by email.
Eight US suppliers, thirty-eight samples, one blinded analytical lab. Every chromatogram, COA, and supplier score — delivered the moment you subscribe.
PDF delivered instantly. No account required. Unsubscribe anytime.
CJC-1295 vs Tesamorelin (2026): Two GHRH Analogs, Two Research Stories
A research-framed comparison of CJC-1295 and tesamorelin — both GHRH-analog peptides, but one is a research-built long-acting compound and the other a clinically developed agent with a defined trial record. Mechanism and evidence.
CJC-1295 vs Sermorelin (2026): GHRH Analog Research Comparison
Two GHRH-analog research peptides separated mostly by half-life. A research-framed comparison of structure, the DAC distinction, pulsatility, evidence, and what the half-life gap means for protocol design and sourcing.
TB-500 vs Thymosin Beta-4: Fragment vs Full-Length in the Research Literature
TB-500 and Thymosin Beta-4 are routinely conflated, but one is a synthetic fragment and the other the full-length parent protein. A research-framed look at the structural distinction, the shared active region, and why it matters for sourcing.